Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Dr Graham Kelly, chief executive officer and executive chairman of Noxopharm (ASX:NOX).

With five decades experience in the sector, Dr Kelly founded the cancer drug developer Novogen, now Kazia Therapeutics.

He departed Novogen in 2015 and founded Noxopharm, which is also involved in oncology drug development based on Novogen’s technology platform.

Dr Kelly is now also on the board of Nyrada Inc, which spun off from Noxopharm and listed on the ASX in January after raising $8.5m.

Nyrada is furthering Noxopharm’s non-oncology programs in areas including cholesterol management and traumatic brain injury

So tune in to hear the pair discuss rising prescription drug prices, Trump’s plans for the sector and the coming year for Noxopharm. 

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!